Novo-Nordisk seeks injunction to block launch of Sanofi-Aventis insulin pen

Share this article:

Novo Nordisk has filed legal action in the US to block the launch of Sanofi-Aventis' new Solo-Star insulin injection pen, The Financial Times reports.

Novo Nordisk is seeking an injunction because it claims Sanofi’s Solo-Star pen infringes on the patents on its NovoPen 4.

Sanofi-Aventis’ Solo-Star injection pen, which administers Lantus insulin, was recently approved by the FDA. Sanofi-Aventis launched Solo-Star in France and Germany in May and has plans to introduce it elsewhere across Europe and in the US in the months ahead.

Both insulin pens will be competing in a global insulin market worth up to $8.2 billion.

Sanofi-Aventis said in the Financial Times report that it disagreed with Novo Nordisk’s claims and would “vigorously defend” its rights.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?